[go: up one dir, main page]

SG47803A1 - Rapamycin formulations for oral administration - Google Patents

Rapamycin formulations for oral administration

Info

Publication number
SG47803A1
SG47803A1 SG1996004442A SG1996004442A SG47803A1 SG 47803 A1 SG47803 A1 SG 47803A1 SG 1996004442 A SG1996004442 A SG 1996004442A SG 1996004442 A SG1996004442 A SG 1996004442A SG 47803 A1 SG47803 A1 SG 47803A1
Authority
SG
Singapore
Prior art keywords
oral administration
volume
rapamycin formulations
rapamycin
formulations
Prior art date
Application number
SG1996004442A
Other languages
English (en)
Inventor
Christian Luther Ofslager
Maureen Murphy Harrison
Thomas Waymond Leonard
Robert Paul Waranis
Original Assignee
American Home Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Prod filed Critical American Home Prod
Publication of SG47803A1 publication Critical patent/SG47803A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277Preparation processes; Proliposomes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
SG1996004442A 1993-09-30 1994-09-29 Rapamycin formulations for oral administration SG47803A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12952993A 1993-09-30 1993-09-30
US12952393A 1993-09-30 1993-09-30

Publications (1)

Publication Number Publication Date
SG47803A1 true SG47803A1 (en) 1998-04-17

Family

ID=26827648

Family Applications (1)

Application Number Title Priority Date Filing Date
SG1996004442A SG47803A1 (en) 1993-09-30 1994-09-29 Rapamycin formulations for oral administration

Country Status (12)

Country Link
EP (1) EP0648494B1 (nl)
AT (1) ATE173628T1 (nl)
AU (1) AU688782B2 (nl)
DE (2) DE69414810T2 (nl)
DK (1) DK0648494T3 (nl)
ES (1) ES2124852T3 (nl)
FI (1) FI115033B (nl)
GR (1) GR3029439T3 (nl)
HU (1) HU220870B1 (nl)
LU (1) LU90832I2 (nl)
NL (1) NL300055I2 (nl)
SG (1) SG47803A1 (nl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH686761A5 (de) 1993-05-27 1996-06-28 Sandoz Ag Galenische Formulierungen.
DE4336434A1 (de) * 1993-10-26 1995-04-27 Hoechst Ag Pharmazeutische Zubereitung für die parenterale, enterale und dermale Verabreichung von praktisch unlöslichen Arzneistoffen und Verfahren zu ihrer Herstellung
MY129435A (en) * 1994-10-26 2007-04-30 Novartis Ag Pharmaceutical microemulsion preconcentrates
FR2736550B1 (fr) 1995-07-14 1998-07-24 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule
GB9601120D0 (en) * 1996-01-19 1996-03-20 Sandoz Ltd Organic compounds
GB2331924A (en) * 1997-12-08 1999-06-09 Phares Pharm Res Nv Lipid compositions and their use
US6682758B1 (en) 1998-12-22 2004-01-27 The United States Of America As Represented By The Department Of Health And Human Services Water-insoluble drug delivery system
CA2356959C (en) * 1998-12-22 2009-03-31 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Water-insoluble drug delivery system
PL216224B1 (pl) 2002-02-01 2014-03-31 Ariad Pharmaceuticals Pochodne rapamycyny zawierające fosfor, kompozycja je zawierająca oraz ich zastosowanie
WO2005110360A2 (en) * 2004-05-18 2005-11-24 Phares Pharmaceutical Research N.V. Compositions for injection
JP5528708B2 (ja) * 2006-02-09 2014-06-25 参天製薬株式会社 安定な製剤ならびにそれらを調製および使用する方法
EP3738592B1 (en) 2013-10-08 2022-01-26 AI Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
JP2017505789A (ja) * 2014-02-11 2017-02-23 ラム・セラピューティクス,インコーポレーテッド リンパ脈管筋腫症の治療のためのラパマイシン
BR112016022598A8 (pt) 2014-04-04 2021-06-29 Ai Therapeutics Inc composição aerossol farmacêutica na forma de um pó seco para liberação pulmonar, forma de dosagem unitária, pacote farmacêutico, kit e uso
CA2963085C (en) 2014-10-07 2023-02-21 Lam Therapeutics, Inc. An inhalable rapamycin formulation for the treatment of pulmonary hypertension

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU543727B2 (en) * 1980-06-02 1985-05-02 Ayerst Mckenna & Harrison Inc. Injectable composition of rapamycin
US5100899A (en) * 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
GB9103430D0 (en) * 1991-02-19 1991-04-03 Smithkline Beecham Plc Novel compound
IL111003A0 (en) * 1993-09-30 1994-11-28 American Home Prod Multi-component oral rapamycin formulation

Also Published As

Publication number Publication date
NL300055I1 (nl) 2001-12-01
ES2124852T3 (es) 1999-02-16
ATE173628T1 (de) 1998-12-15
LU90832I2 (fr) 2001-11-12
HU9402786D0 (en) 1994-12-28
HK1010342A1 (en) 1999-06-17
NL300055I2 (nl) 2002-04-02
AU688782B2 (en) 1998-03-19
EP0648494B1 (en) 1998-11-25
FI944535A0 (fi) 1994-09-29
DE10199046I1 (de) 2002-01-10
DE69414810D1 (de) 1999-01-07
DE69414810T2 (de) 1999-04-22
AU7420594A (en) 1995-04-13
DK0648494T3 (da) 1999-08-09
FI115033B (fi) 2005-02-28
GR3029439T3 (en) 1999-05-28
HU220870B1 (en) 2002-06-29
HUT71115A (en) 1995-11-28
EP0648494A1 (en) 1995-04-19
FI944535L (fi) 1995-03-31

Similar Documents

Publication Publication Date Title
CA2133175A1 (en) Rapamycin formulations for oral administration
CA2133177A1 (en) Rapamycin formulations for oral administration
HU9402786D0 (en) Rapamycin formulations for oral administration
CY2285B1 (en) Liquid compositions containing cyclosporin and process for their preparation
CA2304704A1 (en) Formulations and methods for reducing toxicity of antineoplastic agents
HUT66660A (en) Intermediates for producing 9-[(substituted glicyl)-amido]-6-demetyl-6-deoxy-tetracyclines and pharmaceutical compositions containing them
AU5260993A (en) Phosphonooxymethyl ethers of taxane derivatives
AU9130691A (en) Stable suspension formulations for controlled delivery of pharmaceutical compounds
HU9302329D0 (en) 7-(substituted)-9-|(substituted glycyl)-amino¨-6-desmethyl-6-desoxy-tetracyclines, pharmaceutical preparatives containing them and methods for producing them
HU9302330D0 (en) 7-(substituted)-9-|(substituted glycyl)-amino¨-6-desmethyl-6-desoxy-tetracyclines, pharmaceutical preparatives containing them and methods for producing them
IL128425A0 (en) Taxane derivatives their preparation and pharmaceutical compositions containing them
AU2724292A (en) Antiviral 4-substituted-2-deoxy-2,3-didehydro-derivatives of alpha-d-neuraminic acid
IL109615A (en) Cyclic polypeptide derivatives processes for the preparation thereof and pharmaceutical compositions containing the same
DE69307977D1 (de) Stabilisierte Derivate von Vitamin D2 und D3 enthaltende pharmazeutische Zusammensetzungen
GB9206244D0 (en) Cytotoxic compound from a marine sponge
IL91949A (en) Dispersible formulation containing the free acid form of diclofenac
AU3645489A (en) Insecticidaln'-substituted-n-alkylcarbonyl-n'- acylhydrazines and n'-substituted-n-acyl-n'- alkylcarbonylhydrazines
HUT68958A (en) Arylidene-1-azacycloalkane and aryl-alkyl-1-azacycloalkane derivatives their salts, pharmaceutical compositions containing them, and their preparation
IL107141A0 (en) Phospholipid derivatives containing higher elements of the vth main group,their preparation and pharmaceutical compositions containing them
IL103856A0 (en) Aminoalkyl-substituted 5,6-dihydro-dibenz(b,e)azepin-6,11-dione-11-oximes,their preparation and pharmaceutical compositions containing them
AU659738B2 (en) New pyrrolothienopyrazine compounds, processes for the preparation thereof, and pharmaceutical compositions containing them